5-(tributylstannyl)-2-(triisopropylsilyl)oxazole | 869542-43-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(tributylstannyl)-2-(triisopropylsilyl)oxazole
• CAS: 869542-43-8
• 化学式: C₂₄H₄₉NOSiSn
• 分子量: 514.455
• InChiKey: TWSMTGCRUGWDPG-UHFFFAOYSA-N

物化性质

• 沸点：
  460.5±55.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.62
• 重原子数：
  28
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-(tributylstannyl)-2-(triisopropylsilyl)oxazole 、 6-氰基-2-萘基三氟甲烷磺酸酯 在 四(三苯基膦)钯 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以48%的产率得到6-[2-Tri(propan-2-yl)silyl-1,3-oxazol-5-yl]naphthalene-2-carbonitrile
  参考文献：
  名称：

  [EN] COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS
  [FR] COMPOSITIONS POUR LE TRAITEMENT DE TUMEURS CÉRÉBRALES

  摘要：

  这项即时发明描述了包括放射治疗和赛维特鲁内尔在内或不包括地塞米松的药物组合物和给药方案，以及治疗疾病、疾病或症状的方法。

  公开号：

  WO2020077197A1
• 作为产物：
  描述：

  triisopropyl trifluoromethane sulfonate 在 正丁基锂 、 叔丁基锂 作用下， 以 乙醚 、 正己烷 为溶剂， 反应 14.75h， 生成 5-(tributylstannyl)-2-(triisopropylsilyl)oxazole
  参考文献：
  名称：

  [EN] COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS
  [FR] COMPOSITIONS DESTINÉES AU TRAITEMENT DE TUMEURS CÉRÉBRALES

  摘要：

  这项即时发明描述了包含赛维特龙和/或地塞米松的药物组合物和给药方案，以及治疗疾病、疾病症状的方法。

  公开号：

  WO2019182743A1

文献信息

• [EN] WNT PATHWAY MODULATORS<br/>[FR] MODULATEURS DE LA VOIE WNT
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2014175832A1

  公开（公告）日：2014-10-30

  The invention provides a compound of structure Ar1-Ar2-X-C(R1R2)-C(=O)-N(R3)-Ar3-Ar4 for modulating WNT activity. In this structure, Ar1, Ar2, Ar3 and Ar4 are, independently, optionally substituted aryl or heteroaryl groups; R1 and R3 are, independently, H or optionally substituted alkyl groups; R2 is H or an optionally substituted alkyl group or an alkylene group which, together with the carbon atom to which it is attached and X, forms a non-aromatic ring or an alkylene group which, together with the carbon atom to which it is attached and X and two adjacent atoms of Ar2, forms a non-aromatic ring; X is O, CR4R5, N or NR4, wherein if X is N, it is bonded to R2; R4 is H, optionally substituted alkyl or an alkylene chain, optionally containing a heteroatom and/or a carbonyl group, which, together with the C or N to which it is attached and two adjacent atoms of Ar2, forms a non-aromatic ring; R5 is H, NH2 or an optionally substituted alkyl group.

  该发明提供了一种结构为Ar1-Ar2-X-C(R1R2)-C(=O)-N(R3)-Ar3-Ar4的化合物，用于调节WNT活性。在这种结构中，Ar1、Ar2、Ar3和Ar4分别是可选择取代的芳基或杂环芳基；R1和R3分别是H或可选择取代的烷基；R2是H或可选择取代的烷基或与其连接的碳原子和X形成非芳香环的烷基，或者与其连接的碳原子、X和Ar2的两个相邻原子形成非芳香环的烷基；X是O、CR4R5、N或NR4，如果X是N，则与R2相结合；R4是H、可选择取代的烷基或含有杂原子和/或羰基的烷基链，与其连接的C或N以及Ar2的两个相邻原子形成非芳香环；R5是H、NH2或可选择取代的烷基。
• AMINOPYRAZINE DERIVATIVE AND MEDICINE
  申请人：Fujihara Hidetaka

  公开号：US20110288065A1

  公开（公告）日：2011-11-24

  The present invention relates to a compound represented by general formula [1] satisfying the following (I) or (II), or a pharmaceutical acceptable salt of the compound. (I) X is CH or N; R 1 is a halogen atom,; and R 2 is H, a halogen atom, CN, [2], [3], [8], [9], an —O-alkyl, an —O-(saturated ring), etc. [2]: —C(R C )(R D )(R E ) (R C to R E each are H, an alkyl, etc.) [3]: —N(R F )(R G ) (R F and R G each are H, OH, amino, a (hetero)aryl, etc.) [8]: —C(═O)R L (R L is an alkyl, OH, an alkoxy, amino, etc.) [9]: a (substituted)phenyl; (II) X is >C—C(—O)R 3 (R 3 is a (substituted)amino, an alkoxy, OH, etc.); R 1 is a halogen atom; R 2 is H; R 3 is H or OH; and R 3 and R 4 each are H or an alkyl.

  本发明涉及一种符合以下（I）或（II）的一般式[1]的化合物，或该化合物的药用可接受盐。(I) X为CH或N；R1为卤原子；R2为H、卤原子、CN、[2]、[3]、[8]、[9]、一个—O-烷基、一个—O-(饱和环)等。[2]: —C(RC)(RD)(RE)（RC至RE各自为H、烷基等）[3]: —N(RF)(RG)（RF和RGeach为H、OH、氨基、(杂)芳基等）[8]: —C(═O)RL（RL为烷基、OH、烷氧基、氨基等）[9]: 一个（取代）苯基；(II) X为>C—C(—O)R3（R3为（取代）氨基、烷氧基、OH等）；R1为卤原子；R2为H；R3为H或OH；R3和R4各自为H或烷基。
• AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP2857398A1

  公开（公告）日：2015-04-08

  The main purpose of the invention is to provide a novel aromatic heterocyclic derivative or a pharmaceutically acceptable salt thereof. Examples of the invention include aromatic heterocyclic derivatives represented by general formula [1] and pharmaceutically acceptable salts thereof. In formula [1], R1 represents phenyl optionally substituted with one or two groups selected from the group consisting of halogens ,as well as alkyls and alkoxys optionally substituted by halogens; R2 represents a hydrogen, an alkyl, cycloalkyl, or alkoxy optionally substituted by a halogen, or a heteroaryl optionally substituted by an alkyl; X represents CR3, and Y represents N or CR4, or X represents N, and Y represents CR4; and Z represents CR5 or N.

  该发明的主要目的是提供一种新的芳香杂环衍生物或其药用可接受盐。该发明的示例包括由一般式[1]表示的芳香杂环衍生物和其药用可接受盐。在式[1]中，R1代表苯基，可以选择地取代一个或两个来自卤素、以及选择性地取代为卤素的烷基和烷氧基的基团之一；R2代表氢、烷基、环烷基或选择性地取代为卤素的烷氧基，或选择性地取代为烷基的杂芳基；X代表CR3，Y代表N或CR4，或X代表N，Y代表CR4；Z代表CR5或N。
• Pyrazine Derivatives Useful as Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20090042891A1

  公开（公告）日：2009-02-12

  The present disclosure relates to a compound of formula (I) wherein: A is an optionally substituted monocyclic or polycyclic aryl or heteroaryl group; B is an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 are chosen from a hydrogen atom and specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety chosen from the moiety of formulae (IIa) and (IIb): or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A 2B adenosine receptor.

  本公开涉及一种式（I）的化合物，其中：A是可选取的取代的单环或多环芳基或杂芳基基团；B是可选取的取代的单环含氮杂芳基基团；并且要么a）R1和R2选择自氢原子和指定的取代基，要么b）R2、R1和R1附着的—NH—基团形成式（IIa）和（IIb）的基团：或其药学上可接受的盐或其N-氧化物。本公开还涉及一种治疗患有病理状况或疾病，易于通过拮抗A2B腺苷受体而改善的受试者的方法。
• Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20080275038A1

  公开（公告）日：2008-11-06

  The present disclosure relates to imidazopyridine derivatives of formula (I): The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A 2B adenosine receptor.

  本公开涉及式(I)的咪唑吡啶衍生物。本公开还涉及一种用于治疗患有病理情况或易于通过A2B腺苷受体拮抗改善的疾病的受试者的方法。